LONDON, July 21, 2010 /PRNewswire/ -- In an interview with financial broadcaster http://www.cantos.com, GlaxoSmithKline CEO Andrew Witty says one-offs held back sales growth in Q2 but highlights the strong underlying performance of Emerging Markets, Consumer and Vaccines.
The Pharma boss also points to an unprecedented five new drugs in late stage trials as a sign of the successful restructuring of the group.
Mr Witty tackles the ongoing Avandia controversy and the recent GBP1.6bn payout, saying it was actually in the best interest of the company's shareholders.
The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.
Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email email@example.com or phone +44-207-936-1352.
CONTACT: If you would like to contact us, please firstname.lastname@example.org or phone +44-207-936-1352.